AbbVie Presents Results from Phase III CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
AbbVie has released findings from its Phase III CANOVA trial, which assessed the safety and effectiveness of venetoclax (marketed as VENCLEXTA®/VENCLYXTO®) in combination with dexamethasone (known as VenDex) for patients with relapsed or refractory (R/R) multiple myeloma featuring the t(11;14) genetic abnormality. The study did not demonstrate a significant improvement in progression-free survival (PFS), the primary endpoint of the trial. Patients treated with VenDex experienced a median PFS of 9.9 months, compared to 5.8 months for those on th...